Published in J Clin Oncol on January 01, 1994
Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet (2005) 2.39
Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol (2008) 1.93
Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol (2013) 1.21
Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer (1997) 1.19
Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health (2010) 1.11
Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol (2009) 1.04
Hot flashes: a review of pathophysiology and treatment modalities. Oncologist (2011) 1.02
A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol (2009) 1.00
Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor? Int J Hyperthermia (2010) 0.97
Management of hot flashes in women with breast cancer. Curr Oncol (2010) 0.95
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. Br J Cancer (2008) 0.90
Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer (2010) 0.88
Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J Clin (2013) 0.84
Feasibility study of acupuncture for reducing sleep disturbances and hot flashes in postmenopausal breast cancer survivors. Clin Nurse Spec (2012) 0.84
Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl (2012) 0.82
A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus (2015) 0.82
Breast cancer survivorship issues. Hematol Oncol Clin North Am (2013) 0.82
Levetiracetam for the treatment of hot flashes: a phase II study. Support Care Cancer (2007) 0.79
A practical guide to the management of menopausal symptoms in breast cancer patients. Support Care Cancer (2005) 0.78
Should symptomatic menopausal women be offered hormone therapy? MedGenMed (2006) 0.78
Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat (2016) 0.76
North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause (2015) 0.76
Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health (2012) 0.76
"I Am Hot, Irritable and Feeling Low; What Alternatives do I have Besides Hormone Replacement Therapy?". Malays Fam Physician (2010) 0.75
Gynecologic care for breast cancer survivors: assisting in the transition to wellness. Am J Obstet Gynecol (2011) 0.75
Management of Potential Long-Term Toxicities in Breast Cancer Patients. Curr Breast Cancer Rep (2016) 0.75
How are Interactions Taken into Account in Studies on Conventional and Complementary Therapies for Breast Cancer Patients with Menopausal Complaints? Geburtshilfe Frauenheilkd (2012) 0.75
Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis. Breast Cancer Res Treat (2016) 0.75
Hypnosis for hot flashes among postmenopausal women study: a study protocol of an ongoing randomized clinical trial. BMC Complement Altern Med (2011) 0.75
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med (1991) 7.21
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet (2000) 4.43
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol (1997) 3.04
It is now the age to define the appropriate follow-up of primary breast cancer patients. J Clin Oncol (1994) 3.00
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst (2001) 2.90
Methodologic lessons learned from hot flash studies. J Clin Oncol (2001) 2.82
Megestrol acetate for the prevention of hot flashes. N Engl J Med (1994) 2.72
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol (1998) 2.24
Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol (2000) 2.11
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst (1990) 1.92
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol (1990) 1.74
Current "corrected" calcium concept challenged. Br Med J (1975) 1.66
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol (1998) 1.65
Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg (1993) 1.64
Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med (1999) 1.63
Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther (2011) 1.62
Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg (1997) 1.58
Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg (1993) 1.55
Natural history of hereditary cancer of the breast and colon. Cancer (1982) 1.53
Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys (1995) 1.51
The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer (1986) 1.50
Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys (1996) 1.50
Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol (1984) 1.46
Continuous intravenous infusion of morphine sulfate for control of severe pain in children with terminal malignancy. J Pediatr (1980) 1.45
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43
Soy for breast cancer survivors: a critical review of the literature. J Nutr (2001) 1.43
Increasing the proportion of women in academic medicine: one institution's response. Mayo Clin Proc (1999) 1.42
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Policies for study monitoring and interim reporting of results. J Clin Oncol (1987) 1.41
An update: cancer-associated anorexia as a treatment target. Curr Opin Clin Nutr Metab Care (2001) 1.40
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39
Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group. J Natl Cancer Inst (1990) 1.37
Stopping when the experimental regimen does not appear to help. Stat Med (1994) 1.37
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg (1990) 1.34
Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol (1991) 1.33
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol (1997) 1.31
Physical, psychological and social well-being of women with breast cancer: the influence of disease phase. Psychooncology (2000) 1.30
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol (1998) 1.29
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol (1985) 1.29
Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat (1999) 1.27
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol (1998) 1.26
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg (1995) 1.25
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg (1998) 1.24
Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res (1999) 1.23
Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med (1992) 1.22
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol (1994) 1.18
Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol (1994) 1.18
Malignant fibrous histiocytoma of the heart. A case report and review of the literature. Cancer (1987) 1.16
Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg (1989) 1.16
Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys (1996) 1.16
Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage (1998) 1.15
Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA (1995) 1.15
Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology (1992) 1.15
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol (1999) 1.15
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med (1979) 1.14
Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer (1991) 1.13
A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol (2001) 1.12
Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer (1992) 1.11
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.09
Resection for solitary brain metastasis. Role of adjuvant radiation and prognostic variables in 229 patients. J Neurosurg (1992) 1.09
Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol (1999) 1.08
Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol (1994) 1.08
Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol (1994) 1.08
Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol (1994) 1.07
Induction of adrenal suppression by megestrol acetate. Ann Intern Med (1996) 1.07
Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol (1993) 1.07
Megestrol acetate-induced adrenal suppression. J Clin Oncol (1996) 1.06
Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. J Clin Oncol (1999) 1.05